Literature DB >> 29330289

BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism.

Karina Vázquez-Arreguín1, Jessica Maddox1, Jinsuk Kang1, Dongju Park2, Reuben R Cano1, Rachel E Factor1, Thomas Ludwig2, Dean Tantin3.   

Abstract

The tumor suppressor BRCA1 regulates the DNA damage response (DDR) and other processes that remain incompletely defined. Among these, BRCA1 heterodimerizes with BARD1 to ubiquitylate targets via its N-terminal E3 ligase activity. Here, it is demonstrated that BRCA1 promotes oxidative metabolism by degrading Oct1 (POU2F1), a transcription factor with proglycolytic and tumorigenic effects. BRCA1 E3 ubiquitin ligase mutation skews cells toward a glycolytic metabolic profile while elevating Oct1 protein. CRISPR-mediated Oct1 deletion reverts the glycolytic phenotype. RNA sequencing (RNAseq) confirms deregulation of metabolic genes downstream of Oct1. BRCA1 mediates Oct1 ubiquitylation and degradation, and mutation of two ubiquitylated Oct1 lysines insulates the protein against BRCA1-mediated destabilization. Oct1 deletion in MCF-7 breast cancer cells does not perturb growth in standard culture, but inhibits growth in soft agar and xenograft assays. In primary breast cancer clinical specimens, Oct1 protein levels correlate positively with tumor aggressiveness and inversely with BRCA1. These results identify BRCA1 as an Oct1 ubiquitin ligase that catalyzes Oct1 degradation to promote oxidative metabolism and restrict tumorigenicity. Mol Cancer Res; 16(3); 439-52. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29330289      PMCID: PMC5835178          DOI: 10.1158/1541-7786.MCR-17-0364

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  54 in total

1.  The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation.

Authors:  R Hashizume; M Fukuda; I Maeda; H Nishikawa; D Oyake; Y Yabuki; H Ogata; T Ohta
Journal:  J Biol Chem       Date:  2001-03-06       Impact factor: 5.157

2.  The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent '+4' cell markers.

Authors:  Javier Muñoz; Daniel E Stange; Arnout G Schepers; Marc van de Wetering; Bon-Kyoung Koo; Shalev Itzkovitz; Richard Volckmann; Kevin S Kung; Jan Koster; Sorina Radulescu; Kevin Myant; Rogier Versteeg; Owen J Sansom; Johan H van Es; Nick Barker; Alexander van Oudenaarden; Shabaz Mohammed; Albert J R Heck; Hans Clevers
Journal:  EMBO J       Date:  2012-06-12       Impact factor: 11.598

3.  Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity.

Authors:  H Ruffner; C A Joazeiro; D Hemmati; T Hunter; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

4.  Oct1 loss of function induces a coordinate metabolic shift that opposes tumorigenicity.

Authors:  Arvind Shakya; Robert Cooksey; James E Cox; Victoria Wang; Donald A McClain; Dean Tantin
Journal:  Nat Cell Biol       Date:  2009-02-15       Impact factor: 28.824

5.  VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2.

Authors:  Jaeyoung J Lim; Kun Yang; Barbie Taylor-Harding; W Ruprecht Wiedemeyer; Ronald J Buckanovich
Journal:  Neoplasia       Date:  2014-04       Impact factor: 5.715

6.  A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint.

Authors:  Rui-Hong Wang; Hongtao Yu; Chu-Xia Deng
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-24       Impact factor: 11.205

7.  BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export.

Authors:  Megan Fabbro; Jose A Rodriguez; Richard Baer; Beric R Henderson
Journal:  J Biol Chem       Date:  2002-03-29       Impact factor: 5.157

8.  Oncosecretomics coupled to bioenergetics identifies α-amino adipic acid, isoleucine and GABA as potential biomarkers of cancer: Differential expression of c-Myc, Oct1 and KLF4 coordinates metabolic changes.

Authors:  Nadège Bellance; Lisa Pabst; Genevara Allen; Rodrigue Rossignol; Deepak Nagrath
Journal:  Biochim Biophys Acta       Date:  2012-07-25

9.  Embryonic lethality, decreased erythropoiesis, and defective octamer-dependent promoter activation in Oct-1-deficient mice.

Authors:  Victoria E H Wang; Tara Schmidt; Jianzhu Chen; Phillip A Sharp; Dean Tantin
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

10.  STAT3 is involved in esophageal carcinogenesis through regulation of Oct-1.

Authors:  Zhipeng Wang; Shaojun Zhu; Min Shen; Juanjuan Liu; Meng Wang; Chen Li; Yukun Wang; Anmei Deng; Qibing Mei
Journal:  Carcinogenesis       Date:  2012-11-21       Impact factor: 4.944

View more
  7 in total

1.  Octamer transcription factor-1 induces the Warburg effect via up-regulation of hexokinase 2 in non-small cell lung cancer.

Authors:  Zhen Li; Jin Su; Mingming Sun; Jiaqi Song; Huanran Sun; Jun Fan; Guo Chen; Changliang Shan; Qi Qi; Shuai Zhang
Journal:  Mol Cell Biochem       Date:  2021-05-10       Impact factor: 3.396

Review 2.  The BRCA1/BARD1 ubiquitin ligase and its substrates.

Authors:  Samuel R Witus; Mikaela D Stewart; Rachel E Klevit
Journal:  Biochem J       Date:  2021-09-30       Impact factor: 3.857

Review 3.  Metabolic Reprogramming in Breast Cancer and Its Therapeutic Implications.

Authors:  Nishant Gandhi; Gokul M Das
Journal:  Cells       Date:  2019-01-26       Impact factor: 6.600

4.  Preventing BRCA1/ZBRK1 repressor complex binding to the GOT2 promoter results in accelerated aspartate biosynthesis and promotion of cell proliferation.

Authors:  Ruoxi Hong; Weimin Zhang; Xi Xia; Kai Zhang; Yan Wang; Mengjiao Wu; Jiawen Fan; Jinting Li; Wen Xia; Fei Xu; Jie Chen; Shusen Wang; Qimin Zhan
Journal:  Mol Oncol       Date:  2019-03-01       Impact factor: 6.603

5.  BRCA1/BARD1 site-specific ubiquitylation of nucleosomal H2A is directed by BARD1.

Authors:  Samuel R Witus; Anika L Burrell; Daniel P Farrell; Jianming Kang; Meiling Wang; Jesse M Hansen; Alex Pravat; Lisa M Tuttle; Mikaela D Stewart; Peter S Brzovic; Champak Chatterjee; Weixing Zhao; Frank DiMaio; Justin M Kollman; Rachel E Klevit
Journal:  Nat Struct Mol Biol       Date:  2021-02-15       Impact factor: 15.369

6.  New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL).

Authors:  Diego Gomes Candido Reis; Débora Levy; Luís Alberto de Pádua Covas Lage; Hebert Fabrício Culler; Vanderson Rocha; Sérgio Paulo Bydlowski; Maria Cláudia Nogueira Zerbini; Juliana Pereira
Journal:  Brain Behav       Date:  2021-02-16       Impact factor: 2.708

7.  Oct1/Pou2f1 is selectively required for colon regeneration and regulates colon malignancy.

Authors:  Karina Vázquez-Arreguín; Claire Bensard; John C Schell; Eric Swanson; Xinjian Chen; Jared Rutter; Dean Tantin
Journal:  PLoS Genet       Date:  2019-05-06       Impact factor: 5.917

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.